Esperion Therapeutics, Inc. reported an insider ownership change for Robert E. Hoffman tied to the completion of the company’s merger on July 13, 2026. The Form 4 says the disposition of securities occurred pursuant to the Agreement and Plan of Merger dated May 1, 2026, among Esperion, Essence Parent Inc. and Essence MergerCo Inc., a wholly owned subsidiary of Parent. At the effective time of the merger on July 13, 2026, Essence MergerCo merged with and into Esperion, with Esperion surviving as a wholly owned subsidiary of Essence Parent. As a result, Esperion’s publicly held common stock, par value $0.001 per share, was automatically canceled and converted into merger consideration. For each share of Esperion common stock, holders became entitled to receive $3.16 in cash, without interest, plus one contractual contingent value right, or CVR. The CVR gives holders the right to potential additional cash payments if specified milestones are achieved, subject to applicable withholding taxes. The filing does not provide the detailed milestone terms for the CVRs. The reported ownership change for Hoffman reflects the merger-related disposition of Esperion common stock rather than an open-market sale. The filing notes that the reported holdings included 79,873 restricted stock units. After the effective time, the Esperion common shares covered by the merger were no longer outstanding, and Esperion continued as a private wholly owned subsidiary of Essence Parent. No separate open-market transaction price or transaction code is provided in the filing text beyond the merger consideration of $3.16 per share plus one CVR.